Barclays PLC Inmune Bio, Inc. Transaction History
Barclays PLC
- $288 Billion
- Q1 2024
Shares
4 transactions
Others Institutions Holding INMB
# of Institutions
57Shares Held
2.88MCall Options Held
44.6KPut Options Held
3.5K-
Vanguard Group Inc Valley Forge, PA541KShares$4.37 Million0.0% of portfolio
-
Black Rock Inc. New York, NY240KShares$1.94 Million0.0% of portfolio
-
Mai Capital Management181KShares$1.46 Million0.02% of portfolio
-
Rhenman & Partners Asset Management Ab Stockholm, V7178KShares$1.44 Million0.2% of portfolio
-
Geode Capital Management, LLC Boston, MA171KShares$1.38 Million0.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $145M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...